A Study of Modigraf® (Tacrolimus Granules) to Evaluate the Pharmacokinetics and Long-term Safety and Efficacy in De Novo Pediatric Allograft Liver and Kidney Transplantation Recipients

Inclusion Criteria:

Participant's parent(s) or their legal representative(s), and participant where applicable agrees not to participate in another interventional study while participating in the present study from 1 month before screening to the end of the study.

Exclusion Criteria:

1. Participant has previously received another organ transplant.
2. Participant has a high immunological risk, defined as a panel reactive antibody (PRA) score > 50% in the previous 6 months (only applicable for kidney transplantation recipients).
3. Cold ischemia time of the donor kidney longer than 30 hours (only applicable for kidney transplantation recipients).
4. Bilateral kidney transplantation recipients (only applicable for kidney transplantation recipients).
5. Participant receives an ABO incompatible donor organ.
6. Participant has significant kidney impairment, defined as having serum creatinine ≥ 230 μmol/L (≥ 2.6 mg/dL) prior to transplantation (not applicable for kidney transplantation recipients).
7. Participant has significant liver disease, defined as having elevated alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) and/or total bilirubin (TBL) levels 3 times the upper value of the normal range prior to transplantation (not applicable for liver transplantation recipients).
8. Participants with malignancies or a history of malignancy within the last 5 years.
9. Participant has a significant, uncontrolled systemic infection and/or severe diarrhea, vomiting, active upper gastrointestinal disorder that may affect the absorption of tacrolimus or has an active peptic ulcer.
10. Recipient or donor known to be human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV) positive.
11. Participant requires systemic immunosuppressive medication for any indication other than transplantation.
12. Participants taking or requiring to be treated with medication or substances prohibited by this protocol.
13. Known allergy or intolerance to steroids, macrolide antibiotics, basiliximab, or tacrolimus.
14. Participants with severe primary disease/complications/poor general condition which may be unsuitable for participating in this study.
15. Participant is currently participating in another clinical trial and/or has been taking any other study drug within 1 month prior to screening.
16. Participant is unlikely to comply with the visits scheduled in the protocol.